Publisher
Springer Science and Business Media LLC
Reference48 articles.
1. Eder, J., Sedrani, R. & Wiesmann, C. The discovery of first-in-class drugs: origins and evolution. Nat. Rev. Drug Discov. 13, 577–587 (2014).
2. Hopkins, A. L., Keserü, G. M., Leeson, P. D., Rees, D. C. & Reynolds, C. H. The role of ligand efficiency metrics in drug discovery. Nat. Rev. Drug Discov. 13, 105–121 (2014).
3. Vitaku, E., Smith, D. T. & Njardarson, J. T. Analysis of the structural diversity, substitution patterns, and frequency of nitrogen heterocycles among US FDA approved pharmaceuticals. J. Med. Chem. 57, 10257–10274 (2014).
4. Rotella, D. P. in Advances in Heterocyclic Chemistry vol. 134 (eds Meanwell, N. A. & Lolli, M. L.) 149–183 (Academic Press, 2021).
5. Kabir, E. & Uzzaman, M. A review on biological and medicinal impact of heterocyclic compounds. Res. Chem. 4, 100606 (2022).